Neurizon Therapeutics (ASX:NUZ)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neurizon Therapeutics (ASX:NUZ) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of cessation of securities - NUZ
Updated Investor Presentation and Webinar Reminder
FDA Type C Feedback, HEALEY trial potentially registrational
FDA says HEALEY ALS trial could support NUZ-001 approval pathway
Dr Chris Bremer commences as Neurizon CEO
Change of Director's Interest Notice
Notification of cessation of securities - NUZ
Neurizon Announces Partial Redemption of Convertible Notes
Neurizon agrees US$1.15 million partial convertible note redemption with two-month share sale standstill
Application for quotation of securities - NUZ
NIH funds Expanded Access Program for NUZ-001 in ALS
NIH funds expanded access program for Neurizon's NUZ-001 ALS therapy
Neurizon Appoints Chief Executive Officer
Neurizon appoints Dr Chris Bremer as CEO to lead late-stage ALS drug development
Application for quotation of securities - NUZ
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Neurizon Therapeutics reports FY2026 results, completes HEALEY ALS trial enrolment, and advances NUZ-001 clinical development
Notification regarding unquoted securities - NUZ
Elanco representative appointed as Neurizon Board Observer
Neurizon Completes Initial Drawdown under R&D Facility
Appendix 4C & Quarterly Update
Neurizon Enters Strategic R&D Financing Facility
Neurizon secures $17.5 million R&D financing facility with Dare Capital
Melbourne investor briefing presentation